Thus, the basal level of DNA damage (γH2AX, CHK1, and phosphorylated ATM/ATR substrates) could be a useful marker to select AML patients susceptible to receive this type of combination therapy [96]. This evidence concerns the gene ATR and acute myeloid leukemia.